The MARIPOSA trials - implications for the treatment of EGFR-mutant NSCLC

被引：1

作者：

Ardeshir-Larijani, Fatemeh ^{[1
]}

Ramalingam, Suresh S. ^{[1
]}

机构：

[1] Emory Univ, Sch Med, Winship Canc Inst, Dept Hematol & Med Oncol, Atlanta, GA 30322 USA

来源：

NATURE REVIEWS CLINICAL ONCOLOGY | 2024年 / 21卷 / 11期

关键词：

D O I：

10.1038/s41571-024-00938-3

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

In the past 2 years, substantial improvements have been made in the management of advanced-stage EGFR-mutant non-small-cell lung cancer. Recent studies have suggested added benefit from the combination of third-generation tyrosine-kinase inhibitors with either chemotherapy or a bispecific antibody targeting EGFR and MET. Herein, we summarize these advances and their implications for clinical practice.

引用

页码：767 / 768

页数：2

共 50 条

[1] A new standard for EGFR-mutant NSCLC?
Killock, David
NATURE REVIEWS CLINICAL ONCOLOGY, 2019, 16 (10) : 593 - 593
[2] A new standard for EGFR-mutant NSCLC?
David Killock
Nature Reviews Clinical Oncology, 2019, 16 : 593 - 593
[3] Treatment of advanced EGFR-mutant NSCLC patients: Sequencing matters
Estevinho, F.
Felizardo, M.
Fernandes, G.
Figueiredo, A.
Lopes, A.
PULMONOLOGY, 2019, 25 (05): : 306 - 309
[4] Erlotinib as adjuvant therapy in EGFR-mutant NSCLC
Jassem, Jacek
LANCET RESPIRATORY MEDICINE, 2018, 6 (11): : 808 - 810
[5] EGFR-mutant NSCLC: emerging novel drugs
Ye, Lingyun
Chen, Xiaoxia
Zhou, Fei
CURRENT OPINION IN ONCOLOGY, 2021, 33 (01) : 87 - 94
[6] Amivantamab OK'd for EGFR-Mutant NSCLC
Dolgin, Elie
CANCER DISCOVERY, 2021, 11 (07) : 1604 - 1604
[7] Optimal treatment sequence for untreated EGFR-mutant NSCLC with brain metastases
Miyawaki, Eriko
Kenmotsu, Hirotsugu
Harada, Hideyuki
Mitsuya, Koichi
Mamesaya, Nobuaki
Kawamura, Takahisa
Kobayashi, Haruki
Nakashima, Kazuhisa
Omori, Shota
Wakuda, Kazushige
Ono, Akira
Naito, Tateaki
Murakami, Haruyasu
Endo, Masahiro
Nakasu, Yoko
Takahashi, Toshiaki
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
[8] First line osimertinib for the treatment of patients with advanced EGFR-mutant NSCLC
Ricciuti, Biagio
Chiari, Rita
TRANSLATIONAL LUNG CANCER RESEARCH, 2018, 7 : S127 - S130
[9] Amivantamab Plus Lazertinib vs Osimertinib in First Line, EGFR-Mutant Advanced NSCLC: Patientrelevant Outcomes from MARIPOSA
Nguyen, D.
Besse, B.
Cho, B. C.
Lee, S. -H.
Lee, K. H.
Lu, S.
Cheng, Y.
Yao, Y.
Girard, N.
Lin, C. -C.
Felip, E.
Aguilar, A.
Charoentum, C.
Cruz, F. J. S. M.
Majem, M.
Lim, C. S.
Akamatsu, H.
Hayashi, H.
Yang, J. C. -H.
Kowalyszyn, R.
Tiscoski, K.
Franke, F.
Ponomarenko, D.
Arslan, C.
Forster, M.
Urban, D.
Misch, D.
Delmonte, A.
Montes, L. V. G.
Gadgeel, S. M.
Cruz-Correa, M.
Peguero, J.
Rousey, S.
Gaffar, Y.
Owen, S.
Schuchard, J.
Diels, J.
Sermon, J.
Sun, T.
Ennis, M.
Fennema, E.
Daksh, M.
Sethi, S.
Bauml, J. M.
Garcia Campelo, M. R.
JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S103 - S104
[10] Amivantamab Plus Lazertinib vs Osimertinib in Firstline EGFR-mutant Advanced NSCLC: Longer Follow-up of the MARIPOSA Study
Gadgeel, S.
Cho, B. C.
Lu, S.
Felip, E.
Hayashi, H.
Spira, A. I.
Besse, B.
Thomas, M.
Owen, S.
Kim, Y. J.
Lee, S. -H.
Dias, J. Mourao
Lee, Y. -G.
Zhao, Y.
Fang, Y.
Girard, N.
Liu, Z.
Sun, P.
Oliveira, S. C. Sousa
Shen, H.
Paz-Ares, L.
Matsumoto, S.
Tanaka, H.
Ahmad, A. R.
Andabekov, T.
Sunpaweravong, P.
Ozyilkan, O.
Yang, J. C. -H.
Gottfried, M.
Hernandez, O.
Kimmich, M.
Cortinovis, D.
Kaen, D. L.
Montes, L. V. Garcia
Popat, S.
Newsom-Davis, T.
Xie, J.
Sun, T.
Fennema, E.
Daksh, M.
Ennis, M.
Sethi, S.
Bauml, J. M.
Nguyen, D.
JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S10 - S11

← 1 2 3 4 5 →